Compounded vs. brand-name GLP-1s: is the dosage debate real?

What did @sarahhubes actually say?

She asked a genuinely good question: if someone takes 10 mg of compounded tirzepatide and 10 mg of brand-name tirzepatide, are those doses actually equivalent? She was honest that she has "only been on compounded GLP1 so far" and was crowd-sourcing personal experiences to fill a gap in her own knowledge. That transparency is worth acknowledging.

The question itself is one of the most important and underexplored issues in the GLP-1 space right now. Millions of people have been on compounded versions and are either switching to brand-name drugs or comparing notes with people who never left the brand-name track. Whether those milligram-for-milligram numbers mean the same thing is not a settled question, and she was right to flag that uncertainty rather than assume they do.

Does the science back this up?

The short answer is: no, 10 mg does not automatically equal 10 mg across formulations. The FDA has never approved any compounded GLP-1 as bioequivalent to Ozempic, Wegovy, Mounjaro, or Zepbound, and that distinction matters enormously in pharmacology.

Bioequivalence requires rigorous pharmacokinetic testing, meaning studies that measure how a drug is absorbed, distributed, metabolized, and excreted in real human bodies under standardized conditions. Compounded semaglutide and tirzepatide have not gone through that process. A 2023 analysis in the Journal of the American Medical Association (Feldman et al., 2023, JAMA) noted that compounded drug products are exempt from FDA premarket approval requirements, which means their potency, purity, and absorption profiles are not independently verified against the reference listed drug. Additionally, many compounded versions use salt forms, specifically semaglutide sodium or tirzepatide acetate, rather than the base forms used in FDA-approved products. Whether those salt forms behave identically in the body at equivalent doses is an open question with limited published human data.

What did they get wrong (or right)?

She got the skepticism exactly right. Framing this as "I don't know if it is" an apples-to-apples comparison is the correct scientific posture, and it is more accurate than most content in this space, which tends to assume equivalency without evidence.

What she did not address, and what matters clinically, is why the comparison breaks down. It is not just about dose numbers on a label. Compounded formulations can vary in excipients, concentration, reconstitution instructions, and even the specific molecular salt form of the active ingredient. A pharmacy compounding tirzepatide acetate is working with a chemically different compound than the base tirzepatide in Zepbound. The FDA has specifically flagged this in its 2024 guidance documents on compounded semaglutide, noting that semaglutide sodium and semaglutide acetate are not the same as semaglutide base and that dosing assumptions cannot be safely transferred between them. She did not get anything wrong here. She just did not have the full picture, which is understandable given that much of this information is buried in regulatory documents rather than patient-facing resources.

What should you actually know?

The FDA does not recognize any compounded GLP-1 as equivalent to its brand-name counterpart. That is not a political opinion. It is the current regulatory and scientific reality.

This has practical consequences. If you switched from compounded tirzepatide to Zepbound at the "same" dose, your actual exposure to the drug may be different. You might experience more side effects, less efficacy, or a different tolerability profile, not because one product is better, but because the pharmacokinetic behavior may not be identical. A 2024 FDA drug shortage update and associated guidance explicitly stated that compounders using salt forms of semaglutide and tirzepatide cannot assume dose equivalence with FDA-approved products. Patients switching between formulations should work with a prescriber to reassess their starting dose rather than assuming continuity. Personal anecdotes from social media, however well-intentioned, cannot substitute for that individualized clinical assessment.

• Salt forms matter: semaglutide sodium is not the same molecule as semaglutide base.
• Compounded GLP-1 products are not FDA-approved and have not been tested for bioequivalence.
• Switching between compounded and brand-name versions at the same labeled dose is not clinically validated.
• Side effect profiles and efficacy data from clinical trials apply to FDA-approved formulations only.
• Any dose transition between formulations should involve a licensed prescriber reassessing your starting point.